Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy-Reference-Cited by-同舟云学术

Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy

Published:2014-07-27 Issue:7520 Volume:514 Page:112-116
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Tavora Bernardo,Reynolds Louise E.,Batista Silvia,Demircioglu Fevzi,Fernandez Isabelle,Lechertier Tanguy,Lees Delphine M.,Wong Ping-Pui,Alexopoulou Annika,Elia George,Clear Andrew,Ledoux Adeline,Hunter Jill,Perkins Neil,Gribben John G.,Hodivala-Dilke Kairbaan M.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature13541.pdf

Reference30 articles.

1. De Vita, V. T, Hellman, S. & Rosenberg S. A Cancer: Principles and Practice of Oncology (Lippincott Williams and Wilkins, 2001)

2. Rottenberg, S. & Jonkers, J. Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resist. Updat. 11, 51–60 (2008)

3. Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500–504 (2012)

4. Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505–509 (2012)

5. Sun, Y. et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nature Med. 18, 1359–1368 (2012)

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Suppression of FAK Kinase Expression Decreases the Lifetime of Focal Adhesions and Inhibits Migration of Normal and Tumor Epitheliocytes in a Wound Healing Assay;Биохимия;2024-09-14

2. Focal adhesion kinase as a new player in the biology of onco-hematological diseases: the starting evidence;Frontiers in Oncology;2024-08-30

3. Targeting the tumour vasculature: from vessel destruction to promotion;Nature Reviews Cancer;2024-08-29

4. Focal adhesion kinase signaling – tumor vulnerabilities and clinical opportunities;Journal of Cell Science;2024-07-15

5. A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer;Cell Chemical Biology;2024-07